The report details CSL's performance on its corporate responsibility commitments over the 2016/2017 financial year. Key highlights include an increase in the number of employees and a 13% growth in direct value distributed to economies where CSL operates, highlighting the company's commitment to sustainable growth. The report also details CSL's focus on product safety, quality and innovation, resulting in the registration of 25 new products and new indications for serious diseases. Additionally, the report includes a comprehensive overview of CSL's community investment activities, which totalled US$40 million in 2016/2017. These initiatives included support for patient communities, biomedical communities and local communities around the globe, underscoring CSL's commitment to building healthier and more sustainable environments.
